This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cheerleading Tweets From Prana's Harvard Scientist Propel Shares Higher

Prana Biotechnology (PRAN) had one goal Tuesday: Mine deep into the phase II study of its Huntington's disease drug PBT2 to find anything positive to report. A single, positive data point -- even in a study overwhelmingly negative -- would be enough to claim victory and justify moving PBT2 into a phase III study. 

Mission accomplished, as Prana heralded PBT2's benefit on a single measure of cognition in Huntington's disease.  Never mind that Prana analyzed PBT2 using eight different cognitive tests and found only one that worked. [Well, sort of worked, if you count just one of two PBT2 doses barely achieving statistical significance.]

Prana simply took a page from the Elan-bapineuzumab playbook on how to develop placebo-like drugs in neuro-degenerative diseases. Tuesday's Hail Mary press release takes me back to 2009 when Elan tried to fool investors into believing that bapineuzumab was a real Alzheimer's drug.

The Elan story ended badly and Prana's will likely end no better, but not before the company raises more money and probably repeats the entire exercise in the coming months since PBT2 is also being studied in Alzheimer's. I can't want to see the spin from those study results.

Prana shares were up 42% to $10.33 Tuesday afternoon in a frenzy of biotech momentum trading. 

The most amusing twist today in the Prana story, however, was the cheerleading coming from the Twitter account of Dr. Rudy Tanzi, the scientist who invented the "metals hypothesis" upon which PBT2 is based. Tanzi is a professor of neurology at Harvard Medical School but he's also Prana's chief scientific officer.

"Our drug." Tanzi must be tweeting as a Prana employee with a financial stake in the outcome of PBT2. An employee of Harvard Medical School would have to disclose his financial conflict of interest, at a minimum. And I'm not sure many Harvard professors would find it appropriate to tweet about clinical trial data that's disclosed only in a corporate press release and had not been peer reviewed, published or presented at a medical meeting. 

Does Tanzi operate under different rules?

The Tanzi tweets continued all day:

Tanzi must have read my story explaining how the PBT2 study in Huntington's disease failed despite the rosy headline. In response, he tweeted:

Must Read: BioMarin Prices New Drug For Ultra-Rare Disease at $380K Per Year

At which point, Tanzi and I got into a fun Twitter spat:

Unlike Tanzi, I neither went to Harvard or co-wrote a book with Deepak Chopra but I do know when negative clinical study data is being spun:

I was curious about Tanzi's financial conflict relating to Prana, so I asked him to explain:

His reply didn't answer my question:

Facts? Prana issued a press release! So I tried again:

I'm still waiting for Tanzi's response.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,733.58 -157.58 -0.88%
S&P 500 2,059.67 -21.76 -1.05%
NASDAQ 4,762.1030 -55.4910 -1.15%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs